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Liposomes containing phosphatidylserine (PS) has been used for the delivery of
drugs into the intramacrophage milieu. Leishmania (L.) infantum parasites live inside
macrophages and cause a fatal and neglected viscerotropic disease, with a toxic
treatment. Sertraline was studied as a free formulation (SERT) and also entrapped
into phosphatidylserine liposomes (LP-SERT) against intracellular amastigotes and in
a murine model of visceral leishmaniasis. LP-SERT showed a potent activity against
intracellular amastigotes with an EC50 value of 2.5µM. The in vivo efficacy of SERT
demonstrated a therapeutic failure. However, when entrapped into negatively charged
liposomes (−58mV) of 125 nm, it significantly reduced the parasite burden in the mice
liver by 89% at 1 mg/kg, reducing the serum levels of the cytokine IL-6 and upregulating
the levels of the chemokine MCP-1. Histopathological studies demonstrated the
presence of an inflammatory infiltrate with the development of granulomas in the
liver, suggesting the resolution of the infection in the treated group. Delivery studies
showed fluorescent-labeled LP-SERT in the liver and spleen of mice even after 48 h
of administration. This study demonstrates the efficacy of PS liposomes containing
sertraline in experimental VL. Considering the urgent need for VL treatments, the
repurposing approach of SERT could be a promising alternative.
Keywords: leishmania, neglected diseases, drug delivery, liposomes, drug repurposing, sertraline
INTRODUCTION
Leishmaniasis is a neglected infectious disease caused by an intracellular protozoan known as
Leishmania spp. Visceral leishmaniasis (VL) is highly endemic in the South America, where it
is caused by Leishmania (L.) infantum; in the Indian subcontinent; and in the east of Africa,
where the etiologic agent is Leishmania (L.) donovani; the WHO (World Health Organization,
2017) estimates more than 400,000 new cases of VL every year. More than 90% of these cases are
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concentrated in Bangladesh, Brazil, Ethiopia, India, Sudan, and
Southern Sudan (Alvar et al., 2012; World Health Organization,
2017). VL is a chronic and systemic disease affecting liver,
spleen, and bone marrow, and if not adequately treated, it
results in 100% of death. The current therapy is challenging
due to a limited number of available drugs, elevated costs due
to hospitalization, high toxicity, parenteral administration, and
the emergence of resistance to conventional drugs (Alvar et al.,
2012). Limited options are available for the treatment of VL.
In the Indian subcontinent, a single dose of AmBisome and
combination therapy are the preferred treatment options. The
combination of antimony with paromomycin is the choice in East
Africa and Yemen. In the Mediterranean Basin, Middle East, and
Central Asia, AmBisome remains the main choice. According to
the recent PAHO guidelines, AmBisome, SbV, and conventional
AmB are still the recommended drugs for the treatment of VL
in the New World (Chakravarty and Sundar, 2019). Among
candidate drugs for VL is paromomycin, an aminoglycoside
antimicrobial, which showed efficacy as a parenteral drug and
entered for Phase III in 2005 (Croft et al., 2005). Considering the
lack of therapeutic options for the treatment of VL, the need for
novel drugs is evident (Tempone et al., 2017).
Finding new uses for FDA-approved drugs is known as
drug repositioning, and has been considered an excellent
approach for neglected diseases to reduce the costs and time
of the research (Andrews et al., 2014; Huang et al., 2015;
Costa-Silva et al., 2017). Currently, all available drugs for the
clinical treatment of leishmaniases were introduced by the
repositioning approach. Pentamidine, an aromatic diamine, was
first synthesized by May and Baker Co, during the preparation
of antitrypanosomal (Trypanosoma brucei) compounds (Lourie
and Yorke, 1939). The first report describing the activity of
amphotericin B against Leishmania was in 1960 (Furtado et al.,
1960). However, amphotericin B was initially licensed in 1959
for the treatment of progressive and potentially life-threatening
fungal infections (Ostrosky-Zeichner et al., 2003). Miltefosine
(hexadecylphosphocholine) was synthesized as part of an anti-
inflammatory program in 1982 at the pharmaceutical company
Burroughs Wellcome (USA) (Croft and Engel, 2006). A series of
alkyl phospholipids analogs made by Takeda Co. demonstrated
effective in vitro properties as antifungals (Tsushima et al.,
1982), but only 2 years later, these compounds were selected
for screening against Leishmania and trypanosomes at the
Wellcome Research Laboratories (UK). Finally, paromomycin,
an oral broad-spectrum aminoglycoside antibiotic synthesized
in 1959 by Carlo Erba Co. (Botero, 1978), was studied as an
antileishmanial candidate in 1975 (Mattock and Peters, 1975).
Drugs approved for central nervous system like
antidepressants are usually safe and widely used worldwide.
Antidepressants and tricyclic neuroleptic drugs have shown
antileishmanial activity (Evans and Croft, 1994; Chan et al., 1998;
Richardson et al., 2009). Another widely used antidepressant,
imipramine, showed potential antileishmanial effect (Andrade-
Neto et al., 2016), with promising in vivo efficacy (Mukherjee
et al., 2014). Additionally, imipramine has shown to depolarize
the transmembrane mitochondrial potential of L. (L.) donovani
(Mukherjee et al., 2012) and altered the sterol level of Leishmania
(L.) amazonensis (Andrade-Neto et al., 2016). In this context,
sertraline (SERT), a selective serotonin reuptake inhibitor (SSRI),
presents several therapeutic uses, ranging from management
of depression, to control of obsessive–compulsive disorder and
social phobia, to treatment of chronic pain (Kreilgaard et al.,
2008; Santuzzi et al., 2012). Palit and Ali (2008) demonstrated the
activity of SERT against the Indian etiologic agent of VL, L. (L.)
donovani, and demonstrated both in vitro and in vivo efficacy at
elevated doses.
The lethal action of sertraline was also investigated in L.
infantum parasites. The drug induced respiration uncoupling,
with a significant decrease of intracellular ATP level, and
also induced oxidative stress in Leishmania. Metabolomics
data demonstrated an extended metabolic disarray caused by
sertraline, with a remarkable variation of the levels of thiol-
redox and polyamine biosynthetic intermediates, suggesting a
multitarget mechanism of action (Lima et al., 2018).
Drug delivery systems can direct antileishmanial substances
to infected organs (Carvalheiro et al., 2015). Negatively charged
nanoliposomes containing pentavalent antimony has shown
superior efficacy than free pentavalent antimony for experimental
VL treatment due to the targeting ability of these vesicles to
bind host cell receptors, named scavenger receptors (ScavR)
(Tempone et al., 2004).
In this work, we evaluated, for the first time, the in vivo
efficacy of the antidepressant sertraline entrapped into negatively
charged liposomes (LP-SERT) in a VL-experimental murine
model and studied its immunomodulatory effect after treatment.
Additionally, a delivery assay was developed to demonstrate
the targeting ability of LP-SERT to spleen and liver organs. In
vitro studies were also performed to evaluate host cell uptake,
mammalian cytotoxicity, and in vitro efficacy.
MATERIALS AND METHODS
Drugs and Chemicals
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(thiazol blue; MTT), sodium dodecyl sulfate (SDS), M-
199 medium, RPMI-PR-1640 medium (w/o phenol red),
and cholesterol were purchased from Sigma–Aldrich (St.
Louis, MO, USA). Hydrogenated phospholipids were kindly
donated by Lipoid GmbH (Ludwigshafen, Germany).
Sertraline and other analytical reagents were purchased
from Sigma–Aldrich (St. Louis, MO, USA). Molecular
biology reagents are purchased from Life Technologies,
and CBA (cytometric beads array) was purchased from BD
(San Jose, CA, USA).
Parasites and Macrophages
L. (L.) infantum (MHOM/MA67ITMAP263) amastigotes were
maintained by using promastigotes from the culture that were
isolated from the liver of previously infected mice. The animals
were infected with 1 × 108 amastigotes (100 µL) by intra-
peritoneal route. After 15 days post infection (d.p.i.), the
animals were euthanized and the liver was macerated in a tissue
grinder tube containing 5ml of PBS and the amastigotes were
separated by differential centrifugation to obtain a suspension of
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parasites. Promastigotes were maintained in Schneider’s medium
supplemented with 10% fetal bovine serum (FBS) at 24◦C.
Macrophages were collected from the peritoneal cavity of BALB/c
mice by washing with RPMI-1640 medium supplemented with
10% FBS andweremaintained in a 5%CO2-humidified incubator
at 37◦C (Cunha-Júnior et al., 2016).
Experimental Animals
BALB/c mice were obtained from the Instituto Adolfo Lutz
of São Paulo State–Brazil, kept in sterile boxes with absorbent
material, and received food and water ad libitum. BALB/c
mice were infected each month with promastigotes from
the culture to maintain the Leishmania strain. BALB/c mice
were also used to obtain peritoneal macrophages. Animal
experiments were performed with the approval of the
Ethics Committee of Instituto Adolfo Lutz (project CEUA-
IAL/Pasteur 04/2016) in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals
(NIH Publications No. 8023).
Determination of 50% Effective
Concentration (EC50) of SERT and
LP-SERT in Promastigotes and
Amastigotes of L. (L.) infantum
To determine the 50% inhibitory concentration against
promastigotes (final logarithmic phase of growth), SERT was
dissolved in DMSO, and the standard drug (miltefosine) was
dissolved in Mili-Q water; both drugs were diluted in Schneider’s
medium in 96-well microplates with an initial concentration
of 100µM. The promastigotes were counted in a Neubauer
chamber and seeded at 1× 106/well at the final volume of 150 µl.
Controls with DMSO and without drugs were performed. The
plate was incubated for 48 h, and the viability of promastigotes
was determined by MTT assay. Promastigotes incubated without
the drug was used as the viability control. The optical density
was determined using a plate reader FilterMax at 570 nm and the
data analysis was performed using GraphPad Prism 5.0 software
(Mikus and Steverding, 2000).
To determine the EC50 value for SERT and LP-SERT
against L. (L.) infantum intracellular amastigotes, peritoneal
macrophages (1 × 105/well) were collected from the peritoneal
cavity of BALB/c mice added to 16-well chamber slides
(NUNC) and incubated for 24 h at 5% CO2 and 37
◦C. A
two-step washing procedure was performed to eliminate non-
adherent cells. Promastigotes were added at a ratio of 10:1,
using RPMI 1640 supplemented with 2% horse serum (Rebello
et al., 2019), and after 4 h, the extracellular parasites were
removed by washing; fresh medium containing SERT, LP-
SERT, and control were added; and the cells were incubated
at 37◦C for 72 h. The initial concentration of SERT and
miltefosine was 100µM, and that for LP-SERT was 20µM.
At the end of the assay, the slides were stained with
Giemsa and observed using a light microscopy. The EC50 was
determined by the number of infected macrophages in 400 cells
(Yardley and Croft, 2000).
Determination of Cytotoxicity of SERT and
LP-SERT in Mammalian Cells
NCTC cells were seeded at 6 × 104 cells/well in 96-well
microplates and incubated with SERT, LP-SERT, and miltefosine
with 150µM as the highest concentration, for 72 h at 37◦C in
a 5% CO2 humidified incubator. The viability of the cells was
determined by the MTT assay. Control cells were incubated in
the presence of DMSO and without drugs. Viability of 100%
was expressed based on the optical density of control NCTC
cells, after normalization. The selectivity index (SI) was given
by the ratio between the cytotoxicity in NCTC cells and the
anti-parasitic activity of the drugs (Pinto et al., 2014).
In vitro Uptake of LP-SERT by
Macrophages
Macrophages were obtained from the peritoneal cavity of
BALB/c mice and seeded at 5 × 106/well for 24 h in 24-
well plates. The cells were infected with promastigotes at a
ratio of 1:10 (macrophage:parasites). After 4 h of infection,
infected and uninfected cells were treated with rhodamine 123-
labeled liposome (LP-SERT-R123) (10µg/ml). The cells were
scraped from their wells using a sterile cell scraper and the
fluorescence intensity was measured by flow cytometry (Attune-
Life technologies) up to 270min. The excitation and emission
wavelengths were 488 and 575 nm, respectively. A number
of 10,000 events per sample/time were evaluated to observe
the internalization of labeled liposomes. Untreated cells and
liposomes without drug were used as controls.
SERT Entrapment in Liposomes
Encapsulation of SERT was performed as described by Reimão
et al. (2012). Briefly, for the liposome preparation, 6mg of
sertraline was dissolved in methanol and sonicated in a bath
sonicator for 10min at 25◦C (solution A). Solution B consisted
of saturated egg phosphatidylcholine (25mg), saturated egg
phosphatidylserine (7.62mg), and cholesterol (1.81mg) at 7:2:1
mole ratio, dissolved in 1ml of chloroform:methanol (1:1). The
mixture of solutions A and B was further sonicated for 10min.
The mixture was evaporated in a rotary evaporator at 55◦C for
40min in a vacuum and protected from light. A pre-heated
(55◦C) isotonic solution of 2.25% glycerol (1ml, v/v) was added
to the lipid film using glass beads. The swelling process of the
pre-formed liposomes was performed in a rotary evaporator at
55◦C for 60min without vacuum. The liposomes were sonicated
in a bath sonicator under heating (55◦C) for 30min, followed by
extrusion in membranes of 0.8, 0.4, and 0.2 nm. The untrapped
SERT was separated from the liposomes by centrifugation (4,000
g for 15min) (Reimão et al., 2012).
Quantification of SERT Into Liposomes
The concentration of the encapsulated SERT was determined
using an ultra-high-performance liquid chromatography (UPLC)
with a binary AT system (Prominence LC-20; Shimadzu Corp.,
Kyoto, Japan) and an ultraviolet photodiode detector array
(PDA) SPDM20A on a reverse-phase ACE C4 column (4.6mm
× 250mm, 5µm particle size). The wavelength was set at
220 nm. The flow rate was 1 ml/minute using an isocratic method
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with acetonitrile:methanol (7:3 v/v) and 0.1% trifluoroacetic acid
(TFA). The SERT was diluted in isopropanol (1 mg/ml) to obtain
standard solutions in a range of 3.125–400µg/ml, and 20 µl
samples were injected into the column. Results obtained were
extrapolated from a standard curve using a linear regression
curve. The encapsulation efficiency (%EE) was calculated using
the following equation (Stewart, 1980; Ong et al., 2016). Free
SERT is considered the non-entrapped drug. Liposomes were
used in all assays immediately after preparation.
%EE = (total SERT − free SERT)/(total SERT)× 100
Dynamic Light Scattering (DLS)
DLS measurements were applied to obtain the vesicles’ mean
diameter in the absence and presence of SERT, through the
apparent diffusion coefficient measurement. The DLS was
performed in a ZetaSizer ZS90 equipment (Malvern, UK) using
the detector positioned at 90◦ and a He–Ne laser, λ = 632.8 nm,
as a light source. All measurements were performed at 22◦C.
Samples were diluted 20-fold to ensure no multiple scattering
inside the cuvette during the experiments. The results show a
unimodal distribution and represent the average of, at least,
four experiments.
The apparent values of hydrodynamic diameter, which is
related to the diffusional dynamics of a vesicle, were obtained
with the autocorrelation functions and were analyzed by the
cumulant analysis software provided by Malvern. The Dh
determination was calculated by means of Stokes–Einstein, as the
following equation:
Dh =
kBT
3piηDapp
where kB is the Boltzmann constant, T is the absolute
temperature, η is the viscosity of the solvent, and Dh and
Dapp are the hydrodynamic diameter and the apparent diffusion
coefficient, respectively (Costa-Silva et al., 2017).
ζ-Potential
ζ-Potential measurements of PS-containing vesicles in the
absence and presence of SERT were evaluated in order to check
the effect of the drug on the vesicle effective surface charge.
The ζ-potential was performed in a ZetaSizer ZS90 equipment
(Malvern, UK) using the detector positioned at 173◦, a He–Ne
laser, λ = 632.8 nm, as a light source and applying PALS (phase
analysis light scattering) and LDV (Laser Doppler Velocity) to
calculate the electrophoretic mobility and the ζ-potential. The
ζ-potential is a measure of the system stability, since it is able
to give information about the net change at the vesicle surface.
Actually, the ζ-potential is defined as the electrical potential in
the beginning of the so-called double layer, i.e., the slipping plane
of the vesicle surface. In this study, the ζ-potential was obtained
using the electrophoretic mobility, based on the Helmholtz–
Smoluchowski equation, which is used in water-based systems in
the presence of ionic strength (I) > 1mM and particle diameter
(DH),> 100 nm. The measurement for each sample was repeated
for at least three times. In order to avoid multiple scattering,
the samples were diluted 20-fold in the appropriate buffer before
the measurements (Lamy et al., 1966; Costa-Silva et al., 2017).
LP-SERT treatment was analyzed by culture microtitration as
previously reported (Park and Lee, 2008).
Experimental Assay
Dose Translation
The initial dose was calculated based on the human dose,
as follows:
Animal dose (mg/kg) =
(
human Km
animal km
)
× human dose
where mouse Km = 3, human Km = 37 (Reagan-Shaw et al.,
2008).
Determination of the Efficacy of SERT in L. (L.)
Infantum-Infected Mice
Young female BALB/c mice were previously infected with L. (L.)
infantum at 1 × 108 parasites/animal by intra-peritoneal route.
The animals were treated at the 5th d.p.i. by the oral route for 10
consecutive days as follows: Group 1—untreated group; Group
2—SERT at 0.3 mg/kg/day; Group 3—SERT at 1mg/kg/day. Each
group consisted of five animals (n = 5/group). The animals were
euthanized at the 16th d.p.i. and the parasitic load was analyzed
by culture microtitration analysis (Buffet et al., 1995). Sertraline
was dissolved and diluted in saline solution (0.9% m/v).
Determination of the Efficacy of LP-SERT in L. (L.)
Infantum-Infected Mice
Young female BALB/c mice were previously infected with L. (L.)
infantum at 1 × 108 parasites/animal by intra-peritoneal route.
The animals were treated at the 5th d.p.i. by the subcutaneous
route for 10 consecutive days as follows. Group 1—untreated
group; Group 2—LP-SERT at 0.3 mg/kg/day; Group 3—LP-SERT
at 1 mg/kg/day; Group 4—treated group with liposome in the
absence of the drug. Each group consisted of five animals (n =
5/group). The animals were euthanized at the 16th d.p.i. and
the parasitic load was analyzed by culture microtitration analysis
(Buffet et al., 1995). As a control of this experiment, a study was
performed using the free drug in the subcutaneous route in the
same doses. Liposomal sertraline was diluted in isotonic glycerol
solution (2.2% v/v).
Immunomodulatory Studies
Based on the results of the treatment with LP-SERT in L. (L.)
infantum-infected mice, the group treated at 1 mg/kg/day was
chosen for immunomodulatory studies. The serum cytokines
were analyzed by flow cytometry using the CBA kit. The CBA
kit quantifies the cytokines (IL-4, INF-γ, TNF-α, IL-6, IL-10,
and IL-12) and chemokine MCP-1 involved in the inflammatory
response (Costa-Silva et al., 2017). Six populations of beads with
different intensities of fluorescence light conjugate with antibody
of capture for each cytokine were mixed, and after the incubation
with the serum, the samples were analyzed by flow cytometry
(LSR Fortessa).
Histopathology Profile
After the treatment with LP-SERT, the animals were euthanized
and the necropsy was performed with macroscopic and
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microscopic evaluation of the organs (liver and spleen).
Fragments of organs were immediately removed, preserved in
10% buffered formalin, and processed by usual histological
techniques. After these procedures, the slides were stained
with hematoxylin and eosin technique. The analyses were
performed in light microscopy to characterize and describe
histopathological lesions (Guerra et al., 2016).
Targeting of LP-SERT to Spleen and Liver
To confirm the targetability of LP-SERT to spleen and liver of
animals, BALB/c mice were infected with 1 × 108 promastigotes
of L. (L.) infantum; after 10 days of infection, the animals were
treated (one dose) with LP-SERT labeled with fluorescent probe
DIL C18. After 24 h of treatment, the animals were euthanized.
The liver and spleen were removed, and imprint of the organs
was done in glass slides, fixed with 3.5% formaldehyde for 6min,
and washed with phosphate buffered saline (PBS). The PGN
solution (PBS, 0.2% gelatin and 0.15% NaN3) was used for the
permeabilization of the samples containing 0.1% of saponin. The
nucleated cells were labeled with DAPI for 30min (Tempone
et al., 2010). The analyses of the samples were made in a
fluorescent microscopy Nikon Eclipse 80i-D-FL-EPI.
Statistical Analysis
The data obtained were reported as the mean and standard
deviation of duplicate samples from two or three independent
assays. The data were analyzed using GraphPad Prism 5.0
software, using one-way ANOVA for significance testing (P
< 0.05). For the immunomodulatory studies, the data were
analyzed using the non-parametric t-test (P < 0.05).
RESULTS
Determination of the in vitro 50% Effective
Concentration (EC50) and 50% Cytotoxic
Concentration (CC50)
SERT and the standard drug miltefosine were incubated
with promastigotes of L. (L.) infantum and the viability was
determined by theMTT assay. After 48 h of incubation, the drugs
showed EC50 values of 0.7 and 16µM, respectively (Table 1).
SERT was also effective against intracellular amastigotes and
showed an EC50 value of 4.2µM. The liposomal formulation of
SERT (LP-SERT) and miltefosine showed EC50 values of 2.5µM
and EC50 3.1µM, respectively. The mammalian cytotoxicity was
evaluated using NCTC cells after 72 h of incubation, and the
viability was determined by MTT assay. The free and liposomal
drug (SERT and LP-SERT) showed CC50 values of 27.4 and
12.0µM, respectively (Table 1).
Internalization of LP-SERT-R123 in
Peritoneal Macrophages
The uptake capacity of Leishmania-infected macrophages and
uninfected macrophages to internalize rhodamine 123-labeled
liposomes was analyzed by flow cytometry. The peak of
internalization of LP-SERT-R123 occurred within the first 30min
for both groups (infected and uninfected macrophages), with
similar levels of fluorescence. At 60min, the fluorescence levels
TABLE 1 | In vitro 50% effective concentration (EC50) of free and liposomal
sertraline against L. (L.) infantum and mammalian cytotoxicity.
EC50 (µM) ± SD
Drugs L. (L) infantum
promastigotes
L. (L) infantum
amastigotes
Cytotoxicity
NCTC cells
S.I.
SERT 0.7 ± 0.4 4.2 ± 2.2 27.4 ± 0.8 6.4
LP-SERT – 2.5 ± 1.6 12.0 ± 2.4 4.8
Miltefosine 16.2 ± 0.02 3.1 ± 1.6 127.7 ± 6.7 40.9
EC50, 50% effective concentration; S.I., selectivity index [CC50 mammalian cells/EC50
L. (L) infantum amastigotes]; SERT, free sertraline; LP-SERT, liposomal sertraline; SD,
standard deviation; EC50 values are representative of three independent assays.
FIGURE 1 | Uptake of liposomal sertraline labeled with rhodamine 123 by
Leishmania-infected and uninfected macrophages. The uptake was measured
by the fluorescence intensity within macrophages using a flow cytometry
(Attune-Thermofisher) for a period of 270min. A number of 10,000 events
were analyzed for each time.
dropped and remained sustained in both groups of macrophages
until 270min (Figure 1).
Physico-Chemical Characterizations of
LP-SERT
In order to characterize the influence of SERT in PS-containing
liposomes, DLS and ζ-potential experiments were performed.
DLS measurements indicated that SERT was not able to alter the
overall size of the liposomes, which showed an average diameter
(Z-average) of ∼127 nm in the absence and 128 nm in the
presence of SERT, respectively. PDI values were also calculated
and remain 0.27 and 0.33 in the absence and presence of SERT,
respectively. The liposome ζ-potential was also unchanged after
the entrapment of SERT, which showed a negatively charged
formulation of −64 ± 4mV in the absence and −58 ± 5mV in
the presence of SERT. Taken together, both DLS and ζ-potential
measurements indicated that the SERT was not able to change
significantly either the vesicle effective diameter or its superficial
charge. The quantification of SERT in liposomes was determined
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by HPLC, using a standard curve of SERT. The Encapsulation
Efficiency (%EE), resulted in a mean value of 80%± 3%.
In vivo Efficacy of SERT
BALB/c mice were infected with L. (L.) infantum (1 × 108
promastigotes) and after 5 d.p.i. the animals were treated for 10
consecutive days with SERT by oral route at 0.3 and 1 mg/kg. The
culture microtitration analysis demonstrated that the treatment
with SERT was not able to reduce the parasite burden when
compared with the untreated group (Figure 2A). Considering
the therapeutic failure of SERT, the drug was entrapped into
negatively charged liposomes and administered by subcutaneous
route using the same doses. The results indicated that the
treatment with LP-SERT was able to reduce the liver parasite
burden by 72% at 0.3 mg/kg (P < 0.05) and by 89% at 1
mg/kg (P < 0.05) when compared with the untreated group.
Free liposomes (without SERT) were used as a control and
demonstrated no efficacy (Figure 2B). The efficacy of free
SERT (unentrapped) was also evaluated by subcutaneous route
and used as an internal control. The free drug was not able
to eliminate the parasites in liver when administered by the
subcutaneous route (Figure 2C). All animals survived after the
treatment with SERT and LP-SERT. During the time of infection
(15 days), 100% of animals survived in the untreated group.
In vivo Immunomodulatory Effect of
LP-SERT
After 10 consecutive days of treatment with LP-SERT, the serum
was collected and the cytokine levels of L. (L.) infantum-infected
BALB/c mice were evaluated by flow cytometry. The results
demonstrated a significant downregulation (two-fold) of the
interleukin 6 (IL-6) levels of the group treated at 1 mg/kg. The
chemokine MCP-1 levels were also significant upregulated in the
treated group (Figure 3). Other cytokines showed undetectable
levels in serum.
Histopathology Profile of BALB/c Mice
Treated With LP-SERT
The spleen and the liver of untreated and animals treated (LP-
SERT at 1 mg/kg) were evaluated using histopathological
techniques. The light microscopy analysis of the slides
demonstrated no significant differences between untreated
infected animals and LP-SERT-treated groups. We observed the
presence of a lymphoid hyperplasia in the spleen (Figures 4A,B)
as well as an inflammatory infiltrate with the development of
granulomas in liver (Figures 4C,D).
Targeting of LP-SERT to Spleen and Liver
The liposomal formulation of SERT was labeled with the
fluorescent probe DIL C18 and administrated by subcutaneous
route in infected L. (L.) infantum BALB/c mice. The fluorescence
microscopy analyses demonstrated that LP-SERT was distributed
to the liver and spleen of the infected animals after 24 h of
administration (Figure 5).
DISCUSSION
VL affects millions of poor people worldwide and remains
without safe therapeutic options; drug repurposing or
repositioning has been an important approach, reducing
time and cost of the research. Previous studies demonstrated
that antidepressants like sertraline and others showed anti-
Leishmania activity (Palit and Ali, 2008; Mukherjee et al., 2012).
Palit and Ali (2008) have demonstrated that SERT eliminated
72 and 70% of parasite burden of spleen and liver, respectively,
using a L. donovani-infected BALB/c mice model. SERT is a
serotonin reuptake inhibitor approved by the Food and Drug
Administration (FDA), and it is widely used in the treatment of
depression (Santuzzi et al., 2012; Onaolapo et al., 2017). In this
study, the therapeutic potential of SERT and LP-SERT against L.
(L.) infantum was determined using in vitro and in vivomodels.
Our studies demonstrated that SERT was 22 times more
effective against promastigotes than the standard drug
miltefosine. SERT was also able to eliminate 100% of intracellular
amastigotes with similar activity to miltefosine, resulting in
an SI of 6. Palit and Ali (2008) previously showed that SERT
was effective against L. (L.) donovani, with EC50 values 1.6-
and 10-fold smaller than our studies with L. (L.) infantum
against promastigotes and intracellular amastigotes, respectively.
Although L. (L.) donovani is also a viscerotropic species, the
differences found in our studies could be ascribed to the
differences in the species between L. (L.) infantum and L. (L.)
donovani, resulting in different drug susceptibilities (Costa-Silva
et al., 2015). Genetic markers for sensibility to specific drugs have
been identified in viscerotropic Leishmania species, specifically L.
(L.) donovani and L. (L.) infantum. The presence of Miltefosine
Sensitivity Locus (MSL) in DNA resulted in a susceptible pattern
to miltefosine, also modifying the clinical responsiveness to
the drug. Leishmania parasites lacking MSL were shown to be
resistant to miltefosine (Carnielli et al., 2018). Additionally,
differences in DNA fingerprint analyses have been identified for
L. (L.) donovani and L. (L.) infantum (Ellis and Crampton, 1991).
Future genetic studies using L. (L.) donovani and L. (L.) infantum
could demonstrate specific genetic markers that contribute to
the response to sertraline.
The use of FDA-approved drugs for drug repositioning
approach has considerable advantages, especially when one
considers the available ADMET data of individual drugs. Data
from the literature report that sertraline has a plasma half-life
(T1/2) of 8 h when orally administered in healthy patients, and
more than 26 h for the plasma terminal T1/2 (Murdoch and
McTavish, 1992). Considering the in vitro potency of sertraline
against L. (L.) infantum, we conducted an in vivo efficacy study in
a murine model, using the following approach: (i) administration
of SERT by oral route; (ii) administration of a daily single dose
for 10 consecutive days; (iii) considering the HED index to
translate doses human↔animal (Reagan-Shaw et al., 2008), a
dose of 1 mg/kg was chosen based on the human equivalent
dose of 0.1 mg/kg; a maximum human dose of sertraline as
an antidepressant drug is 3 mg/kg, but this is followed by
significant increase in adverse effects (Drugbank, 2017). This
murine visceral model of Leishmaniasis has been useful for the
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FIGURE 2 | In vivo efficacy of SERT. After 5 days of infection with L. (L.) infantum, BALB/c mice were treated for 10 consecutive days. (A) Parasite burden (%) of the
treatment with free sertraline in oral administration. (B) Parasite burden (%) of the treatment with liposomal sertraline in subcutaneous administration. (C) Parasite
burden (%) of the treatment with free sertraline in subcutaneous administration. *p < 0.05.
FIGURE 3 | Serum IL-6 (A) and chemokine MCP-1 (B) levels in BALB/c mice infected with L. (L.) infantum treated for 10 consecutive days with LP-SERT at a dose of
1 mg/kg. Cytokine levels (pg/ml) were determined by flow cytometry by the CBA kit (cytometric beads array—BD) (*p < 0.05). It was considered 10,000 events per
analysis. The control is defined by infected and untreated animals.
evaluation of drug candidates. Cunha-Junior et al. evaluated the
time course of the infection using the same strain of L. (L.)
infantum in BALB/c mouse. After intra-peritoneal infection with
1 × 108 stationary-phase promastigotes, the parasite burden
was analyzed by the microtitration method at days 7, 14, 21,
and 30. The infection was well-established after 7 days, with
parasites in the spleen and liver, with increased and sustained
infection for 30 days. Our in vivo assays of oral SERT showed no
reduction of the parasite burden. This result could be ascribed
to multiple factors, including a low oral absorption of SERT,
a poor delivery of SERT, resulting in low tissue concentration
of the drug in the spleen and liver, or the metabolization
of SERT, which could have generated an inactive metabolite
against L. (L.) infantum. Ronfeld et al. (1997) demonstrated that
sertraline has low oral absorption in young human volunteers,
with a Tmax of 7 h. The authors also report a low absorption
for sertraline after oral administration with a Cmax value of
118 ng/ml. Additionally, data from DrugBank (https://www.
drugbank.ca/drugs/DB01104) report that sertraline administered
once daily at 50–200mg for 14 days resulted in steady-state
concentrations after 1 week. Additionally, the drug is extensively
metabolized by the liver to form N-desmethylsertraline, which
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FIGURE 4 | Evaluation of histopathological profile of BALB c mice infected with L. (L.) infantum, after 10 consecutive days of treatment with liposomal sertraline. (A)
Spleen of an animal representative of untreated group. (B) Spleen of an animal representative of the group treated with liposomal sertraline at 1 mg/kg. (C) Liver of an
animal representative of the untreated control group. (D) Liver of an animal representative of the group treated with liposomal sertraline at 1 mg/kg. Presence of
granulomas in all groups (arrows). Staining of H&E, 100× magnification.
has a lower pharmacological antidepressant effect than the
parent compound.
Considering the therapeutic failure of free SERT, we
performed the entrapment of the drug into negatively
charged liposomes containing phosphatidylserine. Sertraline
demonstrated a high entrapment (82%) into the formulation,
resulting in the formation of nanovesicles covered by a negative
charge. Drug delivery systems (DDS) as liposomes have been
widely used in the pharmaceutical field (Kansal et al., 2014).
In the clinical therapy of leishmaniases, DDS have been used
for many years, as the liposomal amphotericin B (Ambisome),
which provides reduced doses, higher safety, and increased
therapeutic index (Ostrosky-Zeichner et al., 2003). In this work,
we observed that the encapsulation of the SERT in negatively
charged liposomes resulted in an in vivo efficacy of the drug,
reducing 72% of the parasitic burden in the liver at doses
below 1 mg/kg. At this dose (1 mg/kg), the parasite burden was
reduced by 89% in the liver. In a previous study, miltefosine was
administered to a BALB/c model infected with L. (L.) infantum
(MHOM/MA67ITMAP263) and resulted in 100% suppression
of the parasite burden in liver and spleen at 7.7 mg/kg (Rebello
et al., 2019).
VL causes strong alterations in the immune system; Ansari
et al. (2006) observed the serum of VL-patients and reported
an increase of the cytokine IL-6, which was associated to the
progressive form of the disease. Murray (2008) studied IL-
6 knockout mice and observed a better outcome of animals
treated with pentavalent antimonial and amphotericin B when
compared to IL-6 competent mice. In our studies, significant
differences of IL-6 levels were observed between treated and
untreated groups. Additionally, the chemokine MCP-1 was
analyzed, and we observed increased serum levels in mice treated
with LP-SERT at 1 mg/kg. Chemokines constitute a family of
chemoattractant cytokines and play a major role in selectively
recruiting monocytes, neutrophils, and lymphocytes, as well as
in inducing chemotaxis through the activation of G-protein-
coupled receptors. Monocyte chemoattractant protein-1 (MCP-
1/CCL2) is one of the key chemokines that regulate migration
and infiltration of monocytes/macrophages (Deshmane et al.,
2009). This chemokine is produced by macrophages, dendritic
cells, and monocytes, and it is an important chemotactic
factor for T cells and natural killer cells (Deshmane et al.,
2009) for the formation of granulomas in the liver, promoting
the extermination of the parasites (Cotterell et al., 1999;
Dey et al., 2007). Our histopathological profile showed an
increase of defense cells as macrophages and dendritic cells,
besides the presence of hepatic granuloma and lymphoid
hyperplasia in the spleen. This fact could be ascribed to
a possible strategy of the organism to activate a response
against the parasite after sertraline exposure. Additionally, these
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FIGURE 5 | Targeting of liposomes (arrow) labeled with DIL C18 (red) containing sertraline in spleen (A) and liver (B) of BALB/c mice. Ten days after infection, the
animals were treated with LP-SERT, spleen and liver were removed, imprinting of each organ have been made in slides, and the samples were submitted to
immunofluorescence analyses at 24 h. Nucleated cells were labeled with DAPI (blue). White bars represent 50 µm.
histopathological data corroborate the increased serum levels
of the monocyte chemoattractant protein (MCP-1) and suggest
the ability of LP-SERT to modulate the immune response of
animals, eliminating L. (L.) infantum in liver. Although LP-
SERT was able to reduce the parasite burden after a course
of 10 days of treatment, the presence of hepatic granuloma
and lymphoid hyperplasia demonstrates an active and unsolved
inflammation. Future studies with higher courses (>10 days) of
LP-SERT administration could contribute to tissue regeneration.
Sertraline was also administered as a free formulation by
the subcutaneous route. Our results demonstrate that free
SERT was not able to reduce the parasite burden at any
tested doses.
The physicochemical properties of liposomes drive the
targeting ability of the formulation, and among them, the
membrane charge and the vesicle size are critical issues.
Negatively charged liposomes containing phosphatidylserine
result in a higher uptake by macrophages via scavenger
receptors (SRs), with an increased in vitro efficacy against
Leishmania (Tempone et al., 2004), and the VL-mice model
(Laverman et al., 1999; Mukherjee et al., 2012). The negative
charge of vesicles (the modulus of the ζ-potential values
>30mV) also prevents aggregation of the vesicles, avoiding
destabilization of the formulation (Walton et al., 2010). Another
important characteristic is the vesicle size; large liposomes
(>400 nm) are rapidly removed from the circulation when
compared to smaller liposomes (<400 nm) (Faleiro et al., 2014).
Considering that Leishmania is located inside the mononuclear
monocyte system in spleen, liver, bone marrow, and lymph
node (Lindoso et al., 2016), a formulation composed of
nanostructures is essential. Reimão et al. (2012) demonstrated
that liposomes smaller than 200 nm were able to reduce 80%
of the parasite burden in bone marrow of L. (L.) infantum-
infected hamsters.
The route of administration directly defines the therapeutic
success of a drug. Previous studies of our group demonstrated
that the subcutaneous route can increase the efficacy of
negatively charged liposomes containing buparvaquone in an
in vivo VL-model (Costa-Silva et al., 2017). Considering
the efficacy of LP-SERT to reduce the parasite burden in
liver of BALB/c mice, we studied the targetability of this
formulation labeled with a fluorescent probe. After 24 h of
the administration, it was possible to observe the presence
of LP-SERT in the liver and spleen of previously infected
animals. These data demonstrated that LP-SERT reached the
Leishmania target organs, releasing the drug at or nearly the
host cells when administrated subcutaneously. Additionally, our
in vitro studies with infected macrophages demonstrated that
LP-SERT-R123 was able to internalize into Leishmania-infected
and uninfected macrophages at similar levels. Dhanikula et al.
(2005) demonstrated that the pharmacokinetics parameters of
the liposomal formulation of paclitaxel were widely distinct
when administrated subcutaneously and intravenously; the drug
bioavailability was improved by the subcutaneous route. Allen
et al. (1993) observed the administration of liposomes in different
routes (subcutaneous, intravenous, and intra-peritoneal); their
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results showed undamaged liposomes in the bloodstream after
passing for the lymphoid chain when administrated via the
subcutaneous route. In our previous studies with liposomal
buparvaquone, the subcutaneous route was also the best option
to improve the drug efficacy and targeting ability.
CONCLUSION
The present study demonstrated that sertraline is a potent in vitro
anti-L. (L.) infantum drug. For the first time in the literature,
sertraline was encapsulated in phophatidylserine liposomes and
studied in an experimental VL-murine model. The liposomal
formulation of sertraline demonstrated the ability to reduce the
parasite burden at low doses, being delivered to the liver and
spleen of infected mice. The study also demonstrated that at
higher doses, the liposomal sertraline can modulate the host
immune response, affecting the course of the disease. Future
pharmacokinetic studies may contribute to understand the action
of this new formulation in VL.
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